• Lee’s Pharmaceutical entered an exclusive licensing deal with 1cBio to develop, make, and commercialize cancer drug candidate OC-3 in Greater China.
• Agreement covers Mainland China, Hong Kong, Macau, Taiwan, and selected Southeast Asian markets.
• Lee’s unit will run GLP safety studies and handle manufacturing work needed for regulatory approvals in the covered markets.
• 1cBio retains rights to use data from the collaboration to support a planned U.S. FDA IND filing.
• OC-3 is a preclinical, PARP1-selective inhibitor targeting tumors with homologous recombination repair defects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260909-12326736), on September 09, 2026, and is solely responsible for the information contained therein.